CD130/gp130 antibody

Catalog No. ABIN2664198

This Rat Monoclonal antibody specifically detects CD130/gp130 in WB, IHC, ELISA, IF, Neut, CyTOF and ICFC. It exhibits reactivity toward Mouse.

Quick Overview for CD130/gp130 antibody (ABIN2664198)

Target: CD130/gp130 (IL6ST) (Interleukin 6 Signal Transducer (Gp130, Oncostatin M Receptor) (IL6ST))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This CD130/gp130 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF), Neutralization (Neut), Cytometry by Time of Flight (CyTOF), Intracellular Flow Cytometry (ICFC)

Clone: 4H1B35

Product Details anti-CD130/gp130 Antibody

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CD130/gp130

Target: CD130/gp130 (IL6ST) (Interleukin 6 Signal Transducer (Gp130, Oncostatin M Receptor) (IL6ST))

Alternative Name: CD130

Background: CD130, also known as gp130 and IL-6ST, is a type I transmembrane glycoprotein. CD130 can form receptor complexes for a family of cytokines, which include IL-6, IL-11, IL-27, LIF, and OSM, and can transduce signals for these cytokines. The 597aa extracellular domain has one Ig-like domain and five fibronectin type-III repeats. The 277a.a. intracellular domain does not have intrinsic kinase activity. Instead, it can be phosphorylated at tyrosine residues after it forms complexes with other receptor subunits, and in turn can lead to the association with JAK tyrosine kinases and the activation of STAT transcription factors, particularly STAT3.

Pathways: JAK-STAT Signaling, Cellular Glucan Metabolic Process, Autophagy, Smooth Muscle Cell Migration, Cancer Immune Checkpoints